Literature DB >> 27557386

Prostate cancer.

Ricardo Alonso Castillejos-Molina, Fernando Bernardo Gabilondo-Navarro.   

Abstract

Prostate cancer is the most frequent tumor found in men worldwide and in Mexico in particular. Age and family history are the main risk factors. The diagnosis is made by prostate biopsy in patients with abnormalities detected in their prostate-specific antigen (PSA) levels or digital rectal exam (DRE). This article reviews screening and diagnostic methods as well as treatment options for patients diagnosed with prostate cancer.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27557386     DOI： 10.21149/spm.v58i2.7797

Source DB:  PubMed          Journal:  Salud Publica Mex        ISSN： 0036-3634


  10 in total

1.  Mental Health in Urologic Oncology.

Authors:  Danyon Anderson; Abrahim N Razzak; Matthew McDonald; David Cao; Jamal Hasoon; Omar Viswanath; Alan D Kaye; Ivan Urits
Journal:  Health Psychol Res       Date:  2022-08-20

Review 2.  The regulatory function of piRNA/PIWI complex in cancer and other human diseases: The role of DNA methylation.

Authors:  Dong-Dong Jia; Hui Jiang; Yi-Fei Zhang; Yu Zhang; Li-Li Qian; Yin-Feng Zhang
Journal:  Int J Biol Sci       Date:  2022-05-09       Impact factor: 10.750

3.  Incidence, Mortality, and Trends of Prostate Cancer in Mexico from 2000 to 2019: Results from the Global Burden of Disease Study 2019.

Authors:  Saul A Beltran-Ontiveros; Martha A Fernandez-Galindo; Jose M Moreno-Ortiz; Jose A Contreras-Gutierrez; Jesus Madueña-Molina; Eliakym Arambula-Meraz; Emir Leal-Leon; Delia M Becerril-Camacho; Veronica J Picos-Cardenas; Carla Angulo-Rojo; Diana Z Velazquez; Francisco Jimenez-Trejo; Francisco Gallardo-Vera; Daniel Diaz
Journal:  Cancers (Basel)       Date:  2022-06-29       Impact factor: 6.575

4.  Factor Analysis and Psychometric Properties Adaption of Chinese Version of the Decisional Engagement Scale (DES-10).

Authors:  Feijie Wang; Lijie Huang; Hongmei Zhang; Hongxia Jiang; Xiaoxia Chang; Yinping Chu; Zhixia Wang; Xiaoli Zhang
Journal:  Patient Prefer Adherence       Date:  2020-10-22       Impact factor: 2.711

5.  Promoter DNA methylation analysis reveals a combined diagnosis of CpG-based biomarker for prostate cancer.

Authors:  Yuanyuan Tang; Shusuan Jiang; Yinmin Gu; Weidong Li; Zengnan Mo; Yuanjie Huang; Tianyu Li; Yanling Hu
Journal:  Oncotarget       Date:  2017-03-22

6.  SU6668 modulates prostate cancer progression by downregulating MTDH/AKT signaling pathway.

Authors:  Benjiang Qian; Yi Yao; Changming Liu; Jiabing Zhang; Huihong Chen; Huizhang Li
Journal:  Int J Oncol       Date:  2017-03-22       Impact factor: 5.650

7.  Disability-Adjusted Life Years for Cancer in 2010⁻2014: A Regional Approach in Mexico.

Authors:  Efrén Murillo-Zamora; Oliver Mendoza-Cano; Mónica Ríos-Silva; Ramón Alberto Sánchez-Piña; Martha Alicia Higareda-Almaraz; Enrique Higareda-Almaraz; Agustin Lugo-Radillo
Journal:  Int J Environ Res Public Health       Date:  2018-04-26       Impact factor: 3.390

8.  MIR-138-5P inhibits the progression of prostate cancer by targeting FOXC1.

Authors:  Hui Huang; Ying Xiong; Zhensheng Wu; Yuhui He; Xianglin Gao; Zhangyan Zhou; Tao Wang
Journal:  Mol Genet Genomic Med       Date:  2020-02-28       Impact factor: 2.183

9.  Metadherin is an apoptotic modulator in prostate cancer through miR-342-3p regulation.

Authors:  Kebang Hu; Xupeng Mu; Helena Kolibaba; Qinan Yin; Chune Liu; Xueqing Liang; Ji Lu
Journal:  Saudi J Biol Sci       Date:  2018-04-22       Impact factor: 4.219

10.  The Effect of Hormone Therapy on the Expression of Prostate Cancer and Multi-Epigenetic Marker Genes in a Population of Iranian Patients.

Authors:  Mahan Mohammadi; Shiva Irani; Iman Salahshourifar; Jalil Hosseini; Afshin Moradi; Farkhondeh Pouresmaeili
Journal:  Cancer Manag Res       Date:  2020-05-19       Impact factor: 3.989
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.